Cargando…
Pharmacokinetic modeling and simulation support for age‐ and weight‐adjusted dosing of dabigatran etexilate in children with venous thromboembolism
BACKGROUND: Dabigatran etexilate (DE), a direct oral thrombin inhibitor, has been evaluated in children with venous thromboembolism (VTE) using oral solution, pellets, or capsules. OBJECTIVES: This study evaluated DE pharmacokinetics (PK) in children with VTE and the appropriateness of a DE pediatri...
Autores principales: | Röshammar, Daniel, Huang, Fenglei, Albisetti, Manuela, Bomgaars, Lisa, Chalmers, Elizabeth, Luciani, Matteo, Halton, Jacqueline, Mitchell, Lesley G., Bergstrand, Martin, Ibrahim, Moustafa M. A., Joseph, David, Tartakovsky, Igor, Gropper, Savion, Brueckmann, Martina, Brandão, Leonardo R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8251571/ https://www.ncbi.nlm.nih.gov/pubmed/33636042 http://dx.doi.org/10.1111/jth.15277 |
Ejemplares similares
-
Design and rationale for the DIVERSITY study: An open‐label, randomized study of dabigatran etexilate for pediatric venous thromboembolism
por: Albisetti, Manuela, et al.
Publicado: (2018) -
Rationale and design of a phase III safety trial of idarucizumab in children receiving dabigatran etexilate for venous thromboembolism
por: Albisetti, Manuela, et al.
Publicado: (2017) -
Phase 3, single‐arm, multicenter study of dabigatran etexilate for secondary prevention of venous thromboembolism in children: Rationale and design
por: Luciani, Matteo, et al.
Publicado: (2018) -
Anticoagulant Effects of Dabigatran on Coagulation Laboratory Parameters in Pediatric Patients: Combined Data from Five Pediatric Clinical Trials
por: Mitchell, Lesley G., et al.
Publicado: (2022) -
Dabigatran in the treatment and secondary prophylaxis of venous thromboembolism in children with thrombophilia
por: Brandão, Leonardo R., et al.
Publicado: (2022)